Clinical Trial Update: Safety and Efficacy of BAY1192631 in Japanese Patients With Methicillin-resistant Staphylococcus Aureus (MRSA) Infections [Phase 3]

View source ↗

Summary

Phase 3 trial update on BAY1192631 in Japanese patients with MRSA infections evaluating safety and efficacy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Methicillin-resistant Staphylococcus Aureus Infections
• Skin Diseases

Drugs mentioned

• BAY1192631

Snippet

Sponsor: Bayer | Conditions: Skin Diseases, Infectious | Phase 3 | Status: COMPLETED | Results posted: 2018-10-04